Tricuspid Valve Interventions Patents: Who Leads, Where the Gaps Are 2026
Tricuspid valve intervention patents: mapping who holds the claim space and what is still open
Concentrated at the top. The five leading assignees hold 74.8% of all 119 records in scope, and the top ten account for every record in the ranking. Filings peaked at 21 in 2018, fell back over the following years, and show renewed growth from 2021 (1 filing) to 2024 (2 filings), a +100% rise over that three-year window. 2025 and 2026 figures are still filling in given the publication lag and should not be read as a decline.
- 1EDWARDS LIFESCIENCES CORP31
- 2OPUS MEDICAL THERAPIES LLC26
- 3HEART REPAIR TECH INC13
- 4EVALVE10
- 5KEPHALIOS9
See the full tricuspid valve interventions analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in tricuspid valve repair devices?
The assignee ranking for this dataset covers 25 companies, with the leader holding 31 of the 119 records in scope and the top five combined accounting for 74.8% of all records. The top ten assignees together cover the entire ranked set, meaning the remaining fifteen ranked companies each hold a comparatively small number of records. This points to a field where a handful of established medical device and hospital-affiliated filers set the pace, and later entrants are filing into already-dense claim territory, particularly around anchoring and coaptation mechanisms.
Is tricuspid valve intervention patent activity growing or slowing?
Filing activity peaked at 21 records in 2018, declined afterward, and has shown renewed growth from 1 filing in 2021 to 2 in 2024, a +100% rise over that three-year window. Counts for 2025 and 2026 are not yet complete because publication typically lags filing by around 18 months, so the most recent years understate actual activity. Based on complete-year data through 2024, the trend should be read as a recovery rather than a decline.
What technology areas dominate tricuspid valve intervention patents?
Implant and prosthesis claims under IPC class A61F appear in 97.5% of the 119 records in scope, making device geometry and anchoring mechanics the dominant claim area. Diagnosis and surgical technique claims (A61B) appear in 42.0% of records, and body-fluid handling devices (A61M) in 20.2%. Imaging (G06T) and sterilisation (A61L) classes are present but much smaller, each under 6% of records, suggesting these are secondary or supporting claim elements rather than primary battlegrounds.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Tricuspid Valve Interventions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.